Retail pharmacy can promote disease prevention as healthcare leaders
WHAT IT MEANS AND WHY IT’S IMPORTANT — It stands to reason that as the first line of health care in the community, retail pharmacy can place itself at the forefront of efforts to promote prevention of disease.
(THE NEWS: HHS secretary announced $750 million investment in prevention, public health. For the full story, click here)
The Department of Health and Human Services’ investment in prevention and public health creates a huge opportunity for pharmacy retailers to put their skills and expertise to good use in efforts to prevent disease, particularly those that result from lifestyles, including obesity, cardiovascular disease and Type 2 diabetes.
And now that pharmacists can administer vaccinations, they can help prevent the spread of infectious diseases as well, all the while educating customers about the products and services they offer that help prevent disease and promote healthier living.
Food retailers that operate pharmacies are particularly well-positioned because they can promote the products and services at the pharmacy, while also promoting better eating, especially if they have in-store dietitians and other programs to promote healthy diets.
Elan, Boehringer Ingelheim enter development, manufacturing agreement
DUBLIN — Irish biotech company Elan and German drug maker Boehringer Ingelheim will collaborate to develop and manufacture antibody-based medicines.
The two companies said BI would perform technical development, clinical manufacturing and regulatory filing support, while Elan would lead discovery, preclinical testing, clinical development and commercialization of the drugs. Financial terms of the deal were not disclosed.
“We are excited to collaborate with Boehringer Ingelheim, a highly regarded and world-class leader in biological technical development and manufacturing,” Elan SVP and head of biologic strategy, planning and operations Johannes Roebers said. “The agreement enables Elan to focus resources on discovery and the clinical progression of our science while leveraging Boehringer Ingelheim’s process development and production capabilities.”
Mallinckrodt receives FDA approval for generic Duragesic
ST. LOUIS — The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.
Mallinckrodt, part of Covidien, said the FDA approved its fentanyl transdermal system patch.
The patch is a generic version of Johnson & Johnson’s Duragesic. The drug, an opioid and Class II controlled substance, is used for managing persistent, moderate-to-severe pain that requires continuous opioid administration.